CoQ10 and Fertility: Female, Male & IVF Evidence Explained

CoQ10 and fertility has become one of the largest search topics around this supplement, but “fertility” combines several very different outcomes: egg and ovarian-response markers, sperm parameters, clinical pregnancy, miscarriage and live birth. The evidence is not equally strong for all of them.

Direct answer: CoQ10 has encouraging human evidence for selected female assisted-reproduction outcomes and for several semen parameters in men. The evidence becomes less certain when the endpoint moves from a laboratory or intermediate marker to the outcome that matters most: live birth.

CoQ10 and fertility at a glance

Female fertility: what do randomized trials show?

The 2020 systematic review and meta-analysis pooled five randomized trials involving 449 women undergoing assisted reproduction. Clinical pregnancy occurred in 28.8% of women receiving CoQ10 versus 14.1% of controls, producing an odds ratio of 2.44.

That is a meaningful signal. But live birth did not reach statistical significance: OR 1.67 with a wide 95% confidence interval from 0.66 to 4.25. Miscarriage also did not significantly differ.

The correct conclusion is therefore narrower than many fertility marketing claims: CoQ10 may improve the chance of reaching clinical pregnancy in selected ART populations, but this meta-analysis did not establish a live-birth benefit.

Diminished ovarian reserve and poor ovarian response

A 2024 meta-analysis pooled six randomized trials and 1,529 women with diminished ovarian reserve undergoing IVF/ICSI. CoQ10-containing pretreatment favored clinical pregnancy, number of retrieved oocytes and cycle cancellation.

There is a major caveat: five of the six trials did not test CoQ10 alone. They combined CoQ10 with other active interventions such as vitamin E, DHEA or Femoston. That makes the pooled result relevant to CoQ10-containing strategies, not six independent confirmations of CoQ10 monotherapy.

The 2023 network meta-analysis also found favorable estimates for clinical pregnancy and live birth in poor ovarian response, but network meta-analysis combines direct and indirect comparisons. Those estimates are useful, not definitive.

What does newer 2026 female-fertility evidence add?

A 2026 randomized trial assigned 100 women with poor ovarian response to CoQ10 200 mg twice daily plus folic acid or folic acid alone. CoQ10 improved several ovarian-response measures including retrieved oocytes, antral follicle count and endometrial thickness. However, chemical and clinical pregnancy rates were not significantly different, and live birth was not studied.

A separate 2026 PCOS-IVF cohort reported higher observed pregnancy and live-birth rates in women using CoQ10. Because that study was retrospective and nonrandomized, the association cannot prove that CoQ10 caused the better outcomes.

For a deeper analysis of this side of the evidence, see CoQ10 for Egg Quality, Female Fertility & IVF.

Male fertility: semen parameters are not the same as pregnancy

Male-fertility research is substantial enough to stand on its own. The 2025 CoQ10 meta-analysis included nine studies and 781 men with idiopathic infertility. It reported improvements in sperm concentration, semen volume and total motility. The pooled clinical-pregnancy estimate also favored CoQ10, but it was based on fewer events and had a very wide confidence interval.

A broader 2025 systematic review of male-fertility supplements found that supplements as a class did not provide convincing evidence of improved pregnancy or live birth, even though individual ingredients—including CoQ10—showed semen-parameter signals.

That distinction protects against a common reasoning error: better sperm motility is not automatically a higher live-birth rate.

See CoQ10 for Male Fertility & Sperm Quality for the male evidence.

Does CoQ10 improve egg quality?

“Egg quality” is not measured directly by one simple clinical test. Research usually uses proxies such as oocyte maturity, number of retrieved oocytes, embryo quality, ovarian-response measures and downstream pregnancy outcomes.

CoQ10’s mitochondrial role makes it biologically plausible in oocyte aging, but a plausible mechanism does not let us claim that a supplement “reverses egg aging.” The most defensible human conclusion is that CoQ10 pretreatment has produced favorable ovarian-response and ART signals in selected populations.

What CoQ10 doses have been studied in fertility?

Doses vary widely across fertility studies. Male trials commonly use doses in the approximate 200–300 mg/day range, while a recent poor-ovarian-response randomized trial used 400 mg/day. Other female ART studies have used different doses, formulations and pretreatment durations.

Because the populations and protocols differ, no single “fertility dose” has been proven optimal. A dose used in a male semen trial should not be automatically imported into an IVF protocol.

How long is CoQ10 usually used before fertility treatment?

Many fertility studies use pretreatment measured in weeks or months rather than days. This fits the biological timescale of spermatogenesis and follicular development, but it does not establish one universal pretreatment duration. IVF and ICSI protocols should be coordinated with the fertility team because timing, ovarian reserve, stimulation strategy and other medications matter.

Pregnancy is a separate safety question

Using CoQ10 before conception is not the same question as continuing it during pregnancy. A randomized trial in high-risk pregnant women studied CoQ10 from 20 weeks to delivery and reported lower pre-eclampsia incidence, but that single trial does not establish routine pregnancy supplementation or broad maternal-fetal safety.

Read CoQ10 During Pregnancy before treating preconception evidence as a pregnancy-safety recommendation.

What the fertility evidence does not prove

• It does not prove that CoQ10 reverses ovarian aging.
• It does not prove that every woman with diminished ovarian reserve will produce more usable embryos.
• It does not prove that improved semen parameters guarantee pregnancy.
• It does not establish a consistent live-birth benefit across female or male fertility research.
• It does not prove that ubiquinol is clinically superior to ubiquinone for fertility outcomes.
• It does not justify replacing infertility evaluation, IVF/ICSI planning or treatment of a correctable male-factor cause.

Final verdict

CoQ10 has one of the more credible supplement evidence bases in fertility, but the strength depends on the endpoint. Female ART studies show promising clinical-pregnancy and ovarian-response signals. Male studies show fairly consistent evidence for some semen parameters. The evidence becomes weaker and less certain when the endpoint is live birth.

That means CoQ10 can reasonably be discussed as an adjunct in fertility care, particularly in selected ART or male-factor settings, while still being clear that the supplement is not proven to overcome infertility by itself.

Continue the CoQ10 fertility trail

• CoQ10 for Egg Quality, Female Fertility & IVF
• CoQ10 for Male Fertility & Sperm Quality
• CoQ10 During Pregnancy
• CoQ10 Dosage
• CoQ10 Research Data Center

Medical note: infertility has many female, male and combined causes. Supplement use should not delay appropriate reproductive evaluation, especially when age, ovarian reserve, severe semen abnormalities or time-sensitive treatment decisions are involved.